A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Mar 2018

At a glance

  • Drugs Complement C1 inhibitor protein (Primary)
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPACT
  • Sponsors CSL Behring
  • Most Recent Events

    • 24 Mar 2018 Results of development of population pharmacokinetic pharmacodynamics model and use of this model to assess the relationship between C1INH functional activity levels and the risk of attacks in patients presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 05 Mar 2018 Results assessing pharmacokinetic profile of subcutaneous c1-esterase inhibitor (c1-inh [sc]) in adolescent and adult patients with hereditary angioedema, were presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 05 Mar 2018 Results examining the effects of C1-INH on the Hereditary Angioedema attack rate by anatomical location presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top